). Individual reprints of this article and a bound booklet of the entire Symposium on Oncology Practice: Hematological Malignancies will be available for purchase from our Web site www.mayoclinicproceedings.com. Traditionally, the goal of therapy in chronic lymphocytic leukemia (CLL) has been palliative, with first-line therapy using alkylating agents and/ or involved field radiotherapy (depending on the stage of disease and sites of involvement) because of the older age of affected patients and the low rate of complete remissions (CRs) with no improvement in overall survival despite treatment. With increasing knowledge about the biology, molecular genetics, and prognostic factors of the disease, the philosophy of care for patients with CLL has evolved from palliation to aiming for a potential cure, especially in younger patients. Furthermore, multiple treatment options have emerged, including purine analogues, monoclonal antibodies, and potentially stem cell transplantation. These have been associated with higher frequencies of CRs and longer durations of responses compared to conventional chemotherapy. In addition, a subset of patients treated with chemoimmunotherapy can achieve durable CRs and molecular remissions. This may translate into improved disease-free survival and potentially a "cure." Because of the heterogeneous nature of CLL, new prognostic markers are currently being incorporated into clinical trials to determine their role in routine clinical practice. This review summarizes current therapeutic regimens that are being evaluated in patients with CLL and management of diseaserelated complications.
C hronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in the Western world, accounting for nearly 25% of all leukemias with an estimated annual age-adjusted incidence of 3 per 100,000 persons in the United States. 1, 2 The median age at diagnosis is approximately 70 years, with 81% of the patients being diagnosed at age 60 years or older. 1 Under the World Health Organization classification, CLL is a B-cell neoplasm, and the entity T-cell CLL has been reclassified as Tcell prolymphocytic leukemia (PLL). 3 Recent data from the Surveillance, Epidemiology, and End Results cancer statistics indicate that the 5-year survival of patients with CLL is 73%. 4 
ETIOLOGY
The cause of CLL is unknown. It is the only leukemia not associated with exposure to ionizing radiation, drugs, or chemicals. [5] [6] [7] No convincing evidence exits for a viral etiology. 8 Epidemiological studies have shown that the risk of CLL, and other primary cancers, is increased in relatives of patients with CLL and therefore strongly suggest that genetic susceptibility to CLL occurs in 5% to 10% of patients. [9] [10] [11] [12] [13] [14] [15] [16] [17] At present, no genes have unambiguously been shown to confer an increased risk of CLL. [18] [19] [20] [21] [22] Some, but not all, studies have indicated that the mean age at diagnosis of offsprings is approximately 10 to 20 years earlier than that of their parents (ie, anticipation). 10, 11, 13, 17, [23] [24] [25] [26] [27] No differences in biology (eg, immunoglobulin heavy chain variable region [IgV H ] gene mutational status, IgV H use, ZAP-70 expression, CD38 expression, or cytogenetics) or rates of transformation to non-Hodgkin lymphoma (NHL) have been demonstrated between familial and sporadic cases of CLL. 13, 24, 25, 28, 29 No data are available comparing treatment responses between familial and sporadic cases of CLL.
CLINICAL PRESENTATION
Approximately 50% of patients with CLL are asymptomatic at the time of presentation and are found to have an isolated peripheral lymphocytosis on blood work obtained for an unrelated indication. [30] [31] [32] Constitutional symptoms are present in approximately 15% of patients at diagnosis, with night sweats, weight loss, and fatigue being more frequent than disease-related fever. 33 The most common physical findings are lymphadenopathy followed by splenomegaly and then hepatomegaly. 33 Ex-tranodal involvement of the tonsils and skin has been observed, whereas involvement of the gastrointestinal tract, lungs, pleura, central nervous system, kidneys, and bones is uncommon.
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DIAGNOSIS
The current diagnosis of CLL is based on minor modifications of the criteria originally proposed by the National Cancer Institute (NCI) ( Table 1) . 34, 35 An absolute blood lymphocytosis, lymphocyte count of less than 5 × 10 9 /L, is acceptable provided it is chronic with the characteristic morphology and immunophenotype. 35 A bone marrow evaluation is no longer required for diagnosis but is useful to determine the extent and pattern of involvement and to clarify the etiology of the cytopenias. 35 The morphology and immunophenotype are adequate for diagnosis and to distinguish CLL from other disorders ( Table 2) . 36 Although the typical B-cell CLL immunophenotype is CD5+, CD19+, CD23+, FMC7-, with weak or negative expression of CD22, CD79b, and surface membrane immunoglobulin, there can be some variability in the expression of these surface markers. [37] [38] [39] [40] Therefore, an immunophenotypic scoring system is often used to aid in the diagnosis and differentiation from other B-cell malignancies [41] [42] [43] [44] [45] [46] [47] (Tables 3 and 4 ). Using a highly sensitive flow cytometric technique, a monoclonal B-cell lymphocytosis (MBL) can be detected in 2% to 3% of the general population, increasing to more than 5% for adults aged 60 years or older. 48 The B-cell clones may have a CLL-like immunophenotype or that of other B-cell lymphoproliferative disorders (Table 5) . A higher incidence of MBL (15.0%-57.5%) has been observed in healthy first-degree relatives of individuals affected with CLL, 13.5% to 18.0% of whom have a CLLlike immunophenotype. 49, 50 After a median follow-up of 5 years, approximately 5% of these first-degree relatives with MBL have required treatment. 48 
PROGNOSIS
The natural history of CLL is highly variable. Survival has been shown to correlate with clinical staging. Patients can be classified into low-, intermediate-, and high-risk groups (ie, Rai or Binet classification) on the basis of presenting /L is acceptable provided there is a chronic, absolute increase in blood lymphocytes with the characteristic morphology and immunophenotype. ‡Bone marrow evaluation is no longer required for diagnosis but useful to determine extent and pattern of involvement and clarification of etiology of cytopenias. features (ie, lymphadenopathy, hepatosplenomegaly, anemia, and thrombocytopenia) with median survivals of more than 10 years, 7 to 9 years, and 2 years, respectively (Tables 6 and 7) . 34, 51, 52 However, there is still marked heterogeneity in outcome between different individuals within the same stage. 53 Risk may be further refined by the presence of other adverse prognostic factors, including a lymphocyte doubling time of less than 12 months, atypical morphology, elevated serum β 2 -microglobulin levels, high levels of soluble CD23, elevated serum thymidine kinase levels, and deletions or mutations of the p53 gene (Table 8) . 42, 54, 55 Chromosomal abnormalities are detected in 30% to 50% and in more than 80% of patients by cytogenetic or fluorescence in situ hybridization analyses, respectively. 56, 57 Median survival times for patients with 17p-, 11q-, trisomy 12q, normal karyotype, and 13q-as the sole abnormality were 32, 79, 114, 111, and 133 months, respectively. 57 In multivariate analysis, 17p-and 11q-were associated with shorter overall survival (OS). 57 Recent data suggest that chromosomal translocations may also be an independent prognostic factor for inferior overall survival. 58 The presence of unmutated IgV H genes has been associated with high-risk cytogenetics, 59 ,60 a need for chemotherapy, 61 and shortened survival. [60] [61] [62] Also, IgV H mutational status can segregate the different stages of Binet classification into distinct groups with different survival patterns. 60, 62 However, it is unclear what degree of homology of IgV H genes to germline sequences (ie, 95% or 98%) should be used to define an unmutated phenotype. 63 Recent data suggest that the use of specific IgV H gene segments, such as the V H 3-21 gene, may be associated with an inferior outcome regardless of mutational status. 64 In multivariate analysis, unmutated IgV H status, 17p deletion, 11q deletion, age, white blood cell count, and lactate dehydrogenase levels were independent prognostic factors for survival. 59 Two other series have indicated that unmutated IgV H status and p53 mutation, loss, or dysfunction were independent adverse prognostic factors. 63, 65 Patients with an unmutated IgV H status and/or high-risk interphase cytogenetics may have a shorter progression-free survival (PFS) and OS after therapy with fludarabine and rituximab. 66 Because of the difficulty in sequencing IgV H genes in a clinical laboratory, surrogate markers for IgV H mutational status have been evaluated. CD38 expression correlates with unmutated IgV H genes but is not a surrogate marker for IgV H mutational status; however, it may serve as an independent prognostic variable in patients with CLL. 61, 63, 65, 67, 68 The optimum cutoff level defining CD38-positivity is unclear. 61, 63, 67, 69 Furthermore, CD38 expression may vary during the course of the disease. 67 Gene expression profiles of CLL cells with unmutated IgV H genes are similar to those with mutated IgV H genes, with a limited number of genes being differentially expressed in the subgroups. 70, 71 One such gene is the intracellular protein tyrosine kinase ZAP-70, which plays a critical role in T-cell receptor signaling. The function of ZAP-70 in CLL is unclear but has been postulated to enhance IgM signaling and thereby contribute to the aggressive clinical course of patients with CLL and unmutated IgV H genes. 72 ZAP-70 expression appears to correlate with an unmutated IgV H gene status and inferior outcome. [73] [74] [75] [76] However, its 78 Also, prospective trials are required to verify and establish the role of these prognostic markers in determining the need for therapy 79 and in selecting the type of therapy.
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INDICATIONS FOR TREATMENT
The indications for initiation of therapy for CLL are those recommended by the NCI-sponsored Working Group (Table 9) . 34 Criteria for therapy include B symptoms (ie, fevers, sweats, or weight loss), progressive enlargement of lymph nodes or hepatosplenomegaly, obstructive adenopathy, development of or worsening thrombocytopenia and anemia, immune hemolysis or thrombocytopenia not responsive to corticosteroids, and rapid lymphocyte doubling time. Hyperviscosity due to a high lymphocyte count is uncommon; therefore, a high lymphocyte count in the absence of a rapid doubling time is not an indication for therapy.
ASSESSMENT OF RESPONSE
Evaluation of response to therapy is based on criteria set forth by the NCI-sponsored Working Group (Table 10) . 34 Since the publication of these criteria, newer therapeutic modalities, such as purine analogues, monoclonal antibodies, and stem cell transplantation (SCT), have yielded higher frequencies of complete responses (CRs) and longer durations of responses. The quality of these remissions has been evaluated using a variety of techniques capable of detecting minimal residual disease (MRD). The 2 main approaches for detecting MRD have been multiparametric flow cytometry based on the immunophenotype of the CLL cell and polymerase chain reaction (PCR)-based strategies using either the qualitative consensus IgH PCR or the quantitative allele specific oligonucleotide (to the complementarity determining region 3) PCR, with reported sensitivities of 1 monoclonal B cell in 10 4 normal cells, 1 in 10 2 to 10 4 normal cells, and 1 in 10 4 to 10 5 normal cells, respectively. 81, 82 Eradication of detectable MRD after autologous SCT and chemotherapy or chemoimmunotherapy is associated with an improved outcome, whereas MRD kinetics are more important than absolute MRD levels after allogeneic SCT. [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] Techniques for assessing MRD require standardization, and prospective clinical studies are needed to validate the role of MRD negativity as a surrogate marker for disease eradication and/or improved survival before its incorporation into routine clinical practice.
TREATMENT
INITIAL THERAPY
Despite the failure of randomized trials to demonstrate an improvement in OS between the different treatment regimens and the paucity of data evaluating different therapeutic strategies and achievement of CR on patient quality of life, treatment rationales have been based on observations that patients who achieve a CR are more likely to have a prolonged PFS and OS 92 and the assumption that prolonged time to treatment failure is associated with improved quality of life. Therefore, front-line treatment decisions are usually geared to achieving a CR without increased toxicity.
Alkylating Agents. An individual patient data metaanalysis indicated that immediate treatment with chlorambucil with or without corticosteroids did not result in a survival advantage over deferred chemotherapy (10- /L in the peripheral blood and comprising >30% of total nucleated cells in the bone marrow. †Each cervical, axillary, and inguinal area (whether unilateral or bilateral), spleen, and liver count as 1 area. Therefore, the number of areas of nodal involvement ranges from 1 to 5. ‡Excluding immune-mediated anemia or thrombocytopenia. (Table 11) . [94] [95] [96] [97] In the French Cooperative Group study that compared fludarabine with CAP and mini-ChOP (lower-dose doxorubicin), enrollment in the CAP arm was prematurely closed when interim analysis demonstrated lower response and survival rates with CAP. 96 Therapy with fludarabine was associated with an improved PFS. [94] [95] [96] However, no differences in OS have been detected. More myelosuppression was seen with fludarabine, [95] [96] [97] and higher incidences of adverse effects (all grades) were seen in older patients receiving fludarabine. 97 The lack of survival difference may partly be due to (1) allowing crossover to the other arm if there was no response or disease progression, 95, 96 with a higher likelihood of achieving a response to subsequent treatment with fludarabine in the alkylator arm than with an alkylating agent in the fludarabine arm, 95 (2) lack of significant high-quality responses achieved, [94] [95] [96] [97] and (3) heterogeneity in other unmeasured prognostic variables (eg, proportion of patients with CD38-positive leukemic cells and unmutated IgV H genes).
In an attempt to improve on these response rates and to prevent the development of resistance, fludarabine has been combined with chemotherapeutic agents and/or monoclonal antibodies. Phase 2 studies that have evaluated fludarabine plus cyclophosphamide, administered in a variety of different schedules and dosing, in untreated patients with CLL have demonstrated OR rates of 76% to 100% and CR rates of 21% to 60%, 99,105-108 with a higher proportion of complete responders lacking detectable disease by flow cytometry (ie, <1% CD5 + /CD19 + cells) (Table 11 ).
106-108
Five randomized trials have compared fludarabine alone to fludarabine and cyclophosphamide, fludarabine and epirubicin, or fludarabine and chlorambucil in untreated patients with active CLL. 95, [98] [99] [100] [101] Fludarabine and epirubicin and fludarabine and cyclophosphamide demonstrated superior response rates and PFS compared to single-agent fludarabine and/or single-agent chlorambucil (Table 11) . 98-101 However, no differences in OS have been detected. Although more frequent and severe leukopenia was observed in the fludarabine and cyclophosphamide arm compared to fludarabine alone, 98,99 the incidence of serious infections was similar in both arms. [98] [99] [100] No toxicity data were available for the trial that compared fludarabine to fludarabine and epirubicin. 101 In the United Kingdom CLL4 trial that compared single-agent chlorambucil, single-agent fludarabine, and fludarabine and cyclophosphamide, more hemolytic anemias were observed with chlorambucil therapy. 98 In the Cancer and Leukemia Group B (CALGB) trial that compared single-agent fludarabine, single-agent chlorambucil, and fludarabine and chlorambucil, the fludarabine and chlorambucil arm was prematurely closed because of excessive rates of life-threatening toxicities, including major infections. 95, 109 More recently, an increased frequency of therapyrelated myelodysplasia (MDS) and/or acute myeloid leukemia (AML) was observed in the patients treated with fludarabine and chlorambucil (0.5% vs 0% vs 3.5%, respectively) after a median follow-up of 4.2 years.
110 Similar findings have not been reported in trials using a combination of fludarabine (or cladribine) and cyclophosphamide or cladribine and chlorambucil therapy.
98-100,106-108,111-114
Treatment with fludarabine and mitoxantrone does not appear to yield higher response rates (OR, 83%; CR, not reached⁄⁄ *2-CdA = cladribine; 2-CdA/C = cladribine and cyclophosphamide; 2-CdA/CM = cladribine, cyclophosphamide, and mitoxantrone; 2-CdA/P = cladribine and prednisone; CAP = cyclophosphamide, doxorubicin (Adriamycin), and prednisone; CB = chlorambucil; CB/P = chlorambucil and prednisone; ChOP = cyclophosphamide, hydroxydaunomycin (doxorubicin [low-dose]), vincristine (Oncovin), and prednisone; CR = complete response; F = fludarabine; F/CB = fludarabine and chlorambucil; FE = fludarabine and epirubicin; NR = not reported; NS = not significant; OR = overall response; OS = overall survival; PFI = progression-free interval; PFS = progression-free survival; R = rituximab; TTP = time to progression. 116 Duration of response was 55% at 36 months. Whether the combination of fludarabine, cyclophosphamide, and mitoxantrone is truly superior to fludarabine and cyclophosphamide, fludarabine and epirubicin, or single-agent fludarabine remains to be determined.
Cladribine. Cladribine with or without corticosteroids has been evaluated in previously untreated patients with CLL, with OR rates of 49% to 86% (CR, 10%-47%). 103, 104, 117, 118 These results are comparable to those obtained with singleagent fludarabine. A phase 3 trial compared cladribine plus prednisone vs chlorambucil plus prednisone in previously untreated patients with CLL (Table 11) . 103 Cross over to the other arm was permitted if there was no response or disease progression. Overall response and CRs were superior in the cladribine arm (87% and 47% vs 57% and 12%, respectively; P.0001). At 2 years, PFS was significantly improved in the cladribine arm (46% vs 33%, respectively; P=.01). However, there was no survival difference. Treatment with cladribine combined with chlorambucil does not yield durable responses.
111 After a median follow-up of 5 years, more than 80% of responders had experienced relapse.
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A phase 3 trial compared single-agent cladribine to cladribine plus cyclophosphamide and cladribine plus cyclophosphamide and mitoxantrone (Table 11) . 104 Significantly higher CR rates were obtained in the cladribine plus cyclophosphamide and mitoxantrone arm compared with cladribine alone (36% vs 21%, respectively; P=.004), whereas only a trend for a higher CR was observed with cladribine plus cyclophosphamide compared with cladribine alone (29% vs 21%, respectively; P=.08). Eradication of MRD, as evaluated by immunophenotyping, was higher in the cladribine plus cyclophosphamide and mitoxantrone arm compared with cladribine alone (23% vs 14%, respectively; P=.042). There were no detectable differences in OR, PFS, and OS among the 3 groups.
Pentostatin (Deoxycoformycin). Limited data are available on the use of single-agent pentostatin in untreated patients with CLL (OR, 46%; CR, 0%).
119
Rituximab. Induction Therapy. Previously untreated patients with CLL/small lymphocytic leukemia (SLL) who received single-agent rituximab, a chimeric human-murine anti-CD20 monoclonal antibody, as first-line and maintenance therapy achieved OR rates of 57% (CR, 9%).
120,121
Higher response rates (OR, 90%; CR, 19%) may be obtained when standard-dose rituximab is administered for 8 weeks, instead of 4 weeks, in untreated patients with low tumor burden (Rai stage 0-II). 122 It is unclear whether these responses will be durable because median follow-up is relatively short.
The combination of fludarabine, cyclophosphamide, and rituximab has been assessed in 224 previously untreated patients with CLL. 107 Overall response was 95% (CR, 70%; NPR, 10%; PR, 15%) with 120 (78%) of 153 complete responders having less than 1% CD5 + /CD19 + cells in the marrow by immunophenotyping. Twenty-six percent of patients could not complete all 6 cycles of therapy. Early discontinuation of therapy was significantly associated with advanced Rai or Binet stage, age older than 65 years, hemoglobin level less than 11 g/dL, serum creatinine level greater than 1.4 mg/dL, and β 2 -microglobulin levels greater than 4 mg/dL (P<.05). Median time to progression (TTP) and OS had not yet been reached after more than 36 months. The proportion of patients achieving a CR and less than 1% CD5 + /CD19 + cells was significantly higher than that historically achieved with fludarabine and cyclophosphamide therapy. 106 The addition of 3 doses of rituximab to the fludarabine and cyclophosphamide regimen, in lieu of the single dose administered in the fludarabine, cyclophosphamide, and rituximab regimen, does not appear to improve responses. 123 A phase 3 German CLL Study Group (GCLLSG) trial is currently comparing the combination of fludarabine and cyclophosphamide vs that of fludarabine, cyclophosphamide, and rituximab as frontline therapy in previously untreated patients with CLL. However, a formal comparision of these 2 regimens 102,124 is also needed to determine which is more efficacious without increased toxicity.
The combination of pentostatin, cyclophosphamide, and rituximab appears to yield comparable OR rates (97%) but lower CR rates (33%) compared with that of fludarabine, cyclophosphamide, and rituximab, with eradication of MRD in some patients. 125 However, median follow-up was only 8.6+ months.
Induction and Consolidation Therapy. The CALGB conducted a randomized phase 2 trial of fludarabine with concurrent vs sequential treatment with rituximab in 104 symptomatic, previously untreated patients with CLL. 114, 126 Patients were randomized to either 6 cycles of standarddose and schedule fludarabine alone or 6 cycles of standard-dose and schedule fludarabine plus rituximab. After a 2-month observation period, patients with stable disease or better (ie, CR or PR) were treated with rituximab for 4 weeks. The OR and CR rates after induction therapy were 90% and 33% vs 77% and 15%, respectively. These responses increased to 90% and 47% vs 77% and 28%, respectively, after consolidation therapy with rituximab. Median CHRONIC LYMPHOCYTIC LEUKEMIA follow-up was 43 months. The estimated 2-year PFS was 70% for each arm. Overall survival was similar in both arms.
Using data generated from the aforementioned study 102 and a prior randomized trial, 95 CALGB performed a retrospective comparison of fludarabine monotherapy to fludarabine and rituximab (sequential and concurrent) in previously untreated patients with CLL. 126 Baseline features of the patients were similar with respect to age, sex, stage, and presence of organomegaly. Therapy with fludarabine and rituximab was associated with significantly more ORs (84% vs 63%, respectively; P=.0003) and CRs (38% vs 20%, respectively; P=.002). The combination of fludarabine and rituximab resulted in a significant difference in PFS (67% vs 45%, respectively; P<.0001) and OS (93% vs 81%, respectively; P=.0006) at 2 years.
Consolidation Therapy. Two groups have evaluated the efficacy of rituximab for the treatment of MRD after chemotherapy (ie, chlorambucil and prednisone or fludarabine followed by high-dose cyclophosphamide).
127,128 Serial improvements in response were observed after each phase of therapy, 128 with OR rates of 86% to 100% (CR, 57%-68%).
127,128 The role of rituximab as consolidative therapy needs to be formally evaluated before its incorporation into routine clinical practice.
Alemtuzumab. Induction Therapy. Subcutaneous alemtuzumab, a humanized unconjugated anti-CD52 monoclonal antibody, can produce OR rates of 87% (CR, 19%) as front-line therapy in patients with CLL. 129 Response by tumor site demonstrated that in most patients (95%), the CLL cells were cleared from the blood and that 66% achieved a CR or NPR in the bone marrow. Although 86% of patients with adenopathy had a response, only 29% achieved a CR (all of whom had lymph nodes of <2 cm in diameter). Most responses occurred after 18 weeks of therapy. The median time to treatment failure had not been reached yet (18+ months). No survival data were reported. First-dose reactions typically associated with intravenous administration (ie, rash, nausea, dyspnea, and hypotension) were absent. Reactivation of cytomegalovirus (CMV) occurred in 10% of patients, with 3 patients requiring ganciclovir.
A phase 3 trial indicated that superior responses are obtained with single-agent intravenous alemtuzumab compared with chlorambucil as first-line therapy for CLL patients with active disease (OR, 82.6% vs 54.7%, respectively; P<.001; CR, 22% vs 2%, respectively; P<.0001).
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However, higher incidences of grade 3 or 4 neutropenia, infections, and CMV infections were noted in patients receiving alemtuzumab. Overall survival was not reported.
Consolidation Therapy. Consolidation with singleagent alemtuzumab appears to improve responses (ie, PR or better) obtained with fludarabine in patients with CLL.
131
Alemtuzumab was administered a median of 5 months after fludarabine therapy. Nine of 11 patients were converted from NPR to CR (with 5 achieving a molecular CR), 12 of 14 patients in PR to either an NPR (n=2) or a CR (n=10) (with 6 achieving a molecular CR), and 7 of 10 patients in CR to a molecular CR. Although there were no cases of CMV disease, oral ganciclovir was used to treat CMV reactivation in 15 (57%) patients.
The efficacy of alemtuzumab for the treatment of MRD is being evaluated further in 2 phase 2 trials; alemtuzumab was administered (intravenously or subcutaneously) for 6 weeks following 4 months of standard-dose and schedule fludarabine.
132,133 Cytomegalovirus reactivation occurred in 14% (with 1 fatality and 1 persistent disease despite therapy) and 17% of patients receiving intravenous or subcutaneous alemtuzumab, respectively. Alemtuzumab was able to convert a proportion of patients with stable disease or PR after fludarabine to PRs and/or CRs. Although higher OR rates were achieved in patients receiving alemtuzumab intravenously (OR, 92% vs 66%, and CR, 42% vs 22%, respectively), it is unclear whether intravenous administration of alemtuzumab is superior to subcutaneous administration because lower response rates were obtained with fludarabine treatment in the patients who received alemtuzumab subcutaneously. Less infusion-related toxicities were seen with subcutaneous administration.
The GCLLSG assessed the safety and efficacy of alemtuzumab consolidation in patients with CLL in first remission.
134 Twenty-three patients responding to first-line therapy with fludarabine alone or fludarabine and cyclophosphamide were randomized to either standard-dose alemtuzumab for 12 weeks or observation only. Of the 21 evaluable patients, 11 were randomized to the alemtuzumab arm before the study was prematurely stopped because of grade 3 to 4 infections (64%) and grade 4 hematologic toxicities in the alemtuzumab arm (36%). All infections were successfully treated. Five of 6 patients in the alemtuzumab arm achieved a molecular remission in the peripheral blood compared to 0 of 3 patients in the observation arm (P=.048). After a median follow-up of 21.4 months, PFS was superior in the alemtuzumab arm compared to the observation arm (ie, no progression vs 24.7 months, respectively; P=.036). The increased incidence of non-CMV infections observed in the GCLLSG 134 and the CALGB 132 studies compared to the Italian 131 and MD Anderson 135,136 studies (27% and 33% vs <10%, respectively) may be due to the shorter interval between chemotherapy and alemtuzumab administration (2 months vs 5-6 months, respectively). Although alemtuzumab consolidation holds promise, the optimal regimen remains to be determined, and its efficacy needs to be verified in a randomized trial.
SALVAGE THERAPY
Because retrospective data have indicated that response to salvage therapies appears to be strongly associated with response to prior therapies and most patients have been or will be treated with fludarabine or fludarabine-based regimens, relapsed patients have generally been classified into 2 groups based on prior response or exposure to fludarabine: fludarabine naive or fludarabine sensitive and fludarabine refractory. However, the choice of appropriate salvage therapy in relapsed patients is hampered by (1) the lack of randomized trials, including those involving SCT, of patients who have been previously exposed to purine analoguebased regimens 94, 101 and monoclonal antibodies; (2) incomplete data in the currently reported phase 2 studies with respect to prior sensitivity or resistance to purine analogueand/or monoclonal antibody-based treatment regimens; and (3) usually inclusion of both purine analogue-sensitive and analogue-resistant patients and/or alkylator-sensitive and alkylator-resistant patients in the same clinical trial.
Fludarabine (Purine Analogue)-Naive or Fludarabine (Purine Analogue)-Sensitive Patients Alkylating Agents. Although re-treatment of patients, who have received prior therapy with an alklyating agent, with an alkylator-based regimen may induce responses in 21% to 62%, the quality of responses is low (CR, 0%-31%) and the duration of responses usually short (2-18 months). 94, [137] [138] [139] [140] In patients who experience relapse after or were refractory to therapy with fludarabine, alkylatorbased therapy can induce OR rates of 7% to 44% with CR rates of 6% to 22%. 92, 94, 95 Purine Analogues. Fludarabine. In previously treated patients with CLL, most experienced failure with an alkylator-based regimen; OR rates of 12% to 58% with CR rates of 0% to 26% can be obtained with single-agent fludarabine. [141] [142] [143] [144] [145] [146] Overall survival strongly correlated with quality of response achieved (ie, CR vs PR vs no response). 143, 144 Long-term follow-up of 174 patients who received first-line therapy with single-agent fludarabine indicated that 67% who experience relapse will respond to salvage therapy with a fludarabine-based regimen, with 74% of patients responding to rechallenge with singleagent fludarabine. 92 However, no patient who initially failed to respond to fludarabine responded to re-treatment with a fludarabine-containing regimen.
A single phase 3 study compared fludarabine alone to CAP in previously treated and untreated patients with CLL (Table 12) . 94 Patients were stratified based on prior or no prior therapy. However, the proportion of patients who received prior fludarabine was not specified. Subgroup analysis of the previously treated patients demonstrated a superior response rate in favor of fludarabine (OR, 48% vs 27%; P=.036; CR, 13% vs 6%; P value, not significant). However, there was no significant difference in response duration or OS.
Several phase 2 studies have evaluated the efficacy of fludarabine in combination with alkylators (eg, fludarabine and cyclophosphamide), 106, 147, 148 anthracyclines/anthraquinones (eg, fludarabine and doxorubicin or fludarabine and mitoxantrone), 115,149 both alkylators and anthracyclines/ anthraquinones (eg, fludarabine, cyclophosphamide, and mitoxantrone), 103 or other nucleoside analogues. Therapy with fludarabine and cyclophosphamide yielded OR rates of 60% to 94% (CR, 10%-29%) in previously treated patients, a proportion of whom had received prior fludarabine therapy (14%-79%).
106,147,148 Treatment with fludarabine plus doxorubicin 149 or fludarabine plus mitoxantrone 115 appears to yield inferior results to those obtained with fludarabine plus cyclophosphamide. However, most of these patients (72%-83%) had received prior fludarabine in contrast to patients treated with fludarabine plus cyclophosphamide. Treatment with fludarabine, cyclophosphamide, and mitoxantrone appears to yield higher-quality response rates (CR, 50%, with 33% having no detectable disease by flow cytometry and PCR analysis) in patients who have not received prior fludarabine but may be associated with more myelosuppression. 113 Although fludarabine, ara-C, mitoxantrone, and dexamethasone chemotherapy can induce CRs of 60% in previously treated patients (87% who had received prior fludarabine, with at least 19% being fludarabine refractory), granulocyte-colony stimulating factor was required to treat severe myelosuppression. 150 It is unclear whether these results will be durable because 25% to 30% of the patients treated underwent SCT.
Preliminary results for a randomized trial comparing fludarabine alone to fludarabine and epirubicin in previously treated and untreated patients with CLL have been presented (Table 12) . 101 The proportion of patients who received prior fludarabine was not specified. Treatment with fludarabine and epirubicin yielded superior response rates (OR, 88% vs 73%, respectively; P=.026; CR, 29% vs 9%, respectively; P=.0029). The combination of fludarabine and epirubicin resulted in a higher PFS (26 months vs 20 months, respectively; P=.085); however, this did not translate into an improved OS (76 months vs 63 months, respectively; P=.10). Subgroup analysis of the previously treated patients has not been performed. Although response duration and/or OS after fludarabine-based salvage therapies appears to be strongly associated with response to prior therapies (ie, prior alkylating agents only, prior alkylating agents and fludarabine [fludarabine sensitive but relapsed], and prior alkylating agents and fludarabine [alkylator refractory and fludarabine refractory]), 106,113 the true magnitude of the efficacy of the various treatment regimens is hampered by incomplete data concerning patient refractoriness to prior alkylator and/or fludarabine therapies.
Cladribine. Cladribine with or without corticosteroids can induce OR rates of 31% to 68% with CRs of 0% to 31% in previously treated patients with CLL.
118,151-154 These results appear to be comparable to those with single-agent fludarabine, although the duration of responses appears to be shorter with cladribine (4-20 months vs >18 months for fludarabine). However, 7% to 43% of these patients had received prior fludarabine. [151] [152] [153] The European Organisation for Research and Treatment of Cancer performed a randomized controlled trial that compared fludarabine to cladribine in previously treated patients with CLL, but no results have been reported to date.
A small number of patients with CLL have received therapy with cladribine and cyclophosphamide or cladribine, cyclophosphamide, and mitoxantrone. [155] [156] [157] Treatment with cladribine and cyclophosphamide yielded ORs of 45% to 62% (CR, 8%-15%), 155, 156 similar to those obtained with fludarabine and cyclophosphamide therapy. However, these responses do not appear to be as durable (median, 11-12 months) as those obtained with fludarabine and cyclophosphamide, but a higher proportion of patients (85%-95%) had received prior fludarabine therapy. Therapy with cladribine, cyclophosphamide, and mitoxantrone appears to be inferior to both cladribine and cyclophosphamide and fludarabine, cyclophosphamide, and mitoxantrone, with an OR of only 37% (CR, 5%) and median response duration of 5 months.
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Pentostatin. Extremely poor results were seen when pentostatin monotherapy was used in patients with previously treated CLL (OR, 15%-29%; CR, 0%-8%).
119, 158, 159 However, 59% of the patients in at least 1 study had been exposed to prior fludarabine.
159 Twenty-one patients with CLL were treated with pentostatin plus cyclophosphamide. 160 Most had advanced disease, and 87% had received prior fludarabine. Overall survival was 81% (CR, 19%) with a median response duration of only 7 months. Similar to what has been observed with fludarabine-based regimens, response to salvage therapy with cladribine-or pentostatin-based regimens appears to be affected by prior fludarabine exposure.
Rituximab. Induction Therapy. Single-agent rituximab administered at the standard-dose and schedule yielded unimpressive responses in previously treated patients with CLL/SLL (OR, 0%-35%; CR, 0%). [161] [162] [163] [164] Alternative dosages (up to 2250 mg/m 2 per week) and schedules of administration (3 times a week) have improved response rates of single-agent rituximab induction therapy (OR, 36% and 52%, and CR, 0% and 4%, respectively) with median TTP of 8 to 11 months. 165, 166 The GCLLSG evaluated fludarabine and rituximab therapy in previously untreated (n=20) and treated (n=11) patients with CLL. 124 Of the 11 previously treated patients, OR was 90% (CR, 27%; complete remission unconfirmed, 18%). Median duration of response for this subset of patients was not stated. No survival data were reported. Inferior results were obtained when rituximab was combined with either pentostatin or cladribine. 167, 168 The combination of fludarabine, cyclophosphamide, and rituximab was evaluated in 177 previously treated patients with CLL. 169 An OR of 73% (CR, 25%; NPR, 16%; PR, 32%) was obtained. Of 35 patients, 25 (71%) in CR had less than 1% CD5 + /CD19 + cells in the marrow by flow cytometry, and 12 (32%) of 37 patients in CR achieved a molecular remission. With a follow-up of 28 months, the estimated median survival was 42 months. These results have been compared to historical controls treated with the combination of fludarabine and cyclophosphamide and fludarabine with or without prednisone. 170 Overall response and CR for fludarabine and cyclophosphamide and fludarabine with or without prednisone were 67% and 12% and 59% and 13%, respectively. Estimated median survival was 31 months and 19 months, respectively. Multivariate analysis showed that the fludarabine, cyclophosphamide, and rituximab group had a significantly higher CR rate and longer survival compared to the fludarabine and cyclophosphamide and fludarabine with or without prednisone group (P=.0001 and P<.0001, respectively). Median survival for the nonresponders was similar for all 3 groups, suggesting that improved supportive care over time did not have a major impact on survival. A phase 3 trial comparing fludarabine, cyclophosphamide, and rituximab with fludarabine and cyclophosphamide in previously treated patients with CLL is currently under way. The OR rates obtained with fludarabine, cyclophosphamide, and rituximab appear comparable to those obtained with fludarabine and rituximab therapy, albeit in a significantly smaller cohort of previously treated patients. 124 However, in that study, MRD was not evaluated, and follow-up was too short to draw conclusions about survival. 124 A formal comparision of these 2 regimens is warranted.
Therapy with pentostatin, cyclophosphamide, and rituximab can yield OR rates of 75% (CR, 25%), which appear to be comparable to those obtained with fludarabine, cyclophosphamide, and rituximab therapy, although the proportion of patients who had received prior fludarabine was not specified. 171 Median response duration and time to treatment failure were 25 months and 40 months, respectively. Median survival was 44 months.
Alemtuzumab. Induction Therapy. Alemtuzumab has been approved for the treatment of patients with refractory CLL. [172] [173] [174] [175] Most of these patients had advanced stage disease, had received prior fludarabine (55%-100%), and had received 3 or fewer prior therapies. Overall response rates were 31% to 70% with CRs of 0% to 30%. Patients were less likely to respond if they had high-risk disease 172, 173 ; enlarged lymph nodes, especially greater than 5 cm in diameter 172, 173, 176 ; World Health Organization performance status of 2 172 ; and received more than 5 prior therapeutic regimens. 174 The higher quality of the responses (CR, 30% and 26%, with no detectable bone marrow disease by immunophenotyping in 16% of complete responders) achieved in 2 trials may be due to differences in patient characteristics and the duration of therapy with alemtuzumab. 83, 177 Median OS was reported in only 2 studies and ranged from 16 months to 27.5 months. 172, 173 Major toxicities were infusion-related events, infections (including CMV reactivation), neutropenia, and thrombocytopenia.
In an attempt to improve on results obtained with the combination of fludarabine, cyclophosphamide, and rituximab in previously treated patients, alemtuzumab was added to the regimen. 178 Of 66 patients with relapsed or refractory CLL who had received treatment, 36% were fludarabine refractory. Of 44 evaluable patients, the OR rate was 65% (CR, 27%; PR, 38%). Higher OR and CR rates were observed in fludarabine-sensitive patients. Eradication of MRD occurred in 92% of patients in CR. Estimated median TTP and OS were 19 months and 16 months, respectively. The study is currently ongoing.
Three studies have evaluated the efficacy and safety of alemtuzumab combined with rituximab in patients with relapsed or refractory CLL (OR, 0%-67%; CR, 0%-44%). [179] [180] [181] No responses were seen in 1 study, 179 possibly because 6 of 12 patients received lower doses of alemtuzumab, and only 1 course of therapy was administered. 179 Responses may be higher in patients who are not refractory to fludarabine/purine analogues 180, 181 and have less advanced disease. 181 No study reported response duration or OS. In general, a higher frequency and severity of adverse events were seen with alemtuzumab than with rituximab. Cytomegalovirus reactivation occurred in up to 27% of patients.
Consolidation Therapy. Administration of alemtuzumab consolidation therapy to patients with CLL who have achieved a PR, NPR, or CR after chemotherapy can improve response rates.
135, 136 The OR rate was 53% with a response rate of 39% with the 10-mg dose three times a week compared with 65% with the 30-mg dose three times a week (P=.066). Forty-seven percent of patients in NPR achieved CR, and 46% in PR achieved NPR or CR. Residual bone marrow disease cleared in most patients, with 11 (38%) of 29 patients achieving a molecular remission. After a median follow-up of 24 months, median TTP has not been reached in responders. Subgroup analysis indicated a longer TTP in patients with no detectable MRD (not reached vs 15 months, respectively) after a median followup of 18 months. Toxicities included grade 1 to 2 infusionrelated events (common) and infections (mainly CMV reactivation). One patient died of pneumonia, and 3 patients developed Epstein-Barr virus-positive large cell lymphoma (the disease resolved in all 3 patients: spontaneously in 2 and after treatment with cidofovir and immunoglobulin in 1).
Fludarabine-Refractory Patients Up to 37% of previously untreated and 76% of previously treated patients with CLL will not respond to singleagent fludarabine (they will either fail to achieve PR or CR while taking at least 1 fludarabine-containing regimen or experience disease progression while taking fludarabine treatment), 92, [94] [95] [96] [97] [141] [142] [143] [144] [145] [146] and an additional 7% to 14% of patients who were initially sensitive to fludarabine (ie, CR or PR) will experience relapse within 6 months of therapy. 94, 95, 145, 146 Treatment of fludarabine-refractory patients has had limited success. Historically, OR rates of 22% (CR, 1%) with a median survival of 10 months have been obtained after first salvage therapy with a variety of agents, including single-agent purine analogues, purine analogues combined with alkylators or other chemotherapeutic agents, and anthracycline-based regimens. 182 This contrasts with results obtained in patients with fludarabine-sensitive disease, in which ORs of 50% to 80% (CR, 12%-30%) and median survivals of 21 to 36 months can be achieved. 101, 112, 169 In a very select group of fludarabine-refractory patients (ie, those with intermediate-stage disease, good baseline hematological parameters, 3 prior types of therapy, and 6 cycles of fludarabine), a modest response may be seen (OR, 32%; CR, 0%) with an OS of 26 months with singleagent cladribine. 183 However, few patients will fulfill these characteristics, as demonstrated by an accrual time of 4 years for 28 patients. In a small series of patients, the combination of pentostatin and cyclophosphamide appears to improve OR rates (77%) with few CRs (8%), 160 but the durability of these responses and effect on OS are unknown.
Modest responses of short duration have been achieved with single-agent rituximab. 165, 166 Higher response rates (OR, 59%) can be obtained with fludarabine, cyclophosphamide, and rituximab therapy; however, CRs are infrequent (5%), and the durability of responses is unknown. 169 Responses have also been observed with the combination of pentostatin, cyclophosphamide, and rituximab 171 and with rituximab plus CHOP chemotherapy. 184 Single-agent alemtuzumab has activity in this group of patients (OR, 31%-46%; CR, 0%-29%), 83, 172, 173, 176, 185 with a proportion of complete responders having no detectable bone marrow disease by immunophenotyping. 83 Higher responses were seen in patients who had received fewer than 3 prior types of therapy 83 with no significant adenopathy (none or nodes <2 cm in diameter). 83, 172 The combination of alemtuzumab and fludarabine may yield higher responses, even in patients refractory to single-agent alemtuzumab and singleagent fludarabine (OR, 83%; CR, 16%; PR, 67%). 186 At this time, it is unclear whether the addition of rituximab to alemtuzumab will improve these results. 179, 180 Because no effective therapies currently exist for patients in whom fludarabine therapy fails, these patients should be encouraged to participate in clinical trials that address this issue.
HEMATOPOIETIC SCT
Autologous SCT. The rationale behind autologous SCT is extrapolated from a linear dose efficacy observed with some chemotherapeutic agents, with higher doses resulting in higher tumor kill. Limitations include potential for reinfusion of the tumor cells, development of secondary MDS, and lack of graft-vs-leukemia (GVL) effect. Contrary to previous reports, administration of fludarabine as first-line therapy does not appear to be associated with a poor collection of peripheral blood stem cells provided mobilization is performed using chemotherapy and granulocyte-colony stimulating factor and an adequate time interval has elapsed between the last dose of fludarabine and leukapheresis. [187] [188] [189] Although autologous SCT is associated with lower treatment-related mortality (TRM) (1%-7%) and can produce molecular remissions, 86, 187, 190 it is unlikely to provide a cure because no evidence exists of a plateau in PFS (Table 13) . 86, 89, 187, 194, 197 Purging of the autograft, CD34 + -positive selection or double selection (CD34 + -positive selection followed by CD19 + -/CD20 + -negative selection), has not been shown to improve relapse rates. 198 Second malignancies, including MDS, skin cancers, lung cancer, NHL, and colorectal and breast cancers, have developed in up to 21% of patients 191, 196, 197 ; development of MDS occurred in 9% to 15% of patients, with 5-year and 8-year actuarial risks posttransplantation being approximately 12%. 191, 197 To identify subgroups of patients who may potentially benefit from an autotransplant, several variables have been evaluated. Predictors of an improved disease-free survival and OS have included a short interval from diagnosis to transplantation, minimal disease (eg, CR) at transplantation, mutated V H status, tumor chemosensitivity, and use of total body irradiation-conditioning regimens. 86, 187, 194, 197, 199 Three randomized trials are under way comparing autotransplantation to chemotherapy in previously untreated patients with advanced CLL (www.ebmt.org/5workingparties /clwp/clwp6.html). 192, 193 Preliminary results from 2 of these trials in younger (ie, <60-66 years) patients with advanced CLL have been reported. 192, 193 Only 1 reported event-free survival outcomes in favor of autotransplantation (median, 63.1 months vs 23.6 months, respectively; P<.001), 192 and none reported OS. Furthermore, up to 30% of patients did not receive the intended autotransplant. 192 Analysis of mutational V H status is ongoing for both trials because it is unclear whether autologous SCT is superior to standard treatment, especially in high-risk patients, eg, those with unmutated V H gene status. 196, 200 Longer-term follow-up is required to determine impact of autotransplantation in patients with advanced-stage and/or high-risk disease. Currently, the use autotransplantation is not recommended outside of a clinical trial.
Allogeneic SCT. The underlying principles of the application of allogeneic SCT are the higher antitumor activity with increased doses of chemotherapy, the GVL effect, and the absence of stem cell contamination. However, allogeneic SCT is associated with increased morbidity and mortality (TRM, up to 50%) because of toxicities from the conditioning regimen, the presence of graft-vs-host disease (GVHD), and infectious complications. Furthermore, feasibility is limited by age restrictions and donor availability. Because first-degree relatives of patients with CLL may harbor a monoclonal population of B cells with a CLL-like immunophenotype, 49, 50 all potential HLA-identical related donors should have peripheral blood evaluated by flow cytometry.
In contrast to autologous SCT, allotransplantation is associated with a plateau in disease-free survival and OS (Table 14) , 89, 202, 203, [205] [206] [207] suggesting that allotransplantation may be curative for some patients. Furthermore, unlike autotransplantation in which disease chemosensitivity is required for the success of the procedure, allogeneic SCT can induce sustained CRs, potentially via a GVL effect, in patients with chemorefractory disease. 203, 206, 207 Allogeneic SCT may also be superior to standard treatment and/or autotransplantation in CLL patients with an unmutated V H gene status. 200, 208 Recent data suggest that patients with negative MRD status have an improved survival rate compared to those with MRD positivity. 83 However, it is unclear whether SCT offers any additional benefit to patients who have already achieved MRD negativity after chemoimmunotherapy. 208 No published randomized trials have compared allogeneic SCT to standard chemotherapy and/or autologous SCT in patients with CLL. The optimal source of stem cells (ie, bone marrow vs peripheral blood), the best conditioning regimen, the timing of transplantation, and patient selection (eg, unfavorable features such as unmutated IgV H , refractory disease) remain to be defined. In younger patients with relapsed disease or highrisk features, allotransplantation may offer a potential for a cure, but the potential gains have to be balanced by the high treatment-related mortality and morbidity.
Nonmyeloablative SCT. Nonmyeloablative (NMA) allogeneic transplantation was developed to minimize the toxicity of the preparative regimen and to exploit the potential for immune-mediated GVL effect. The low-dose NMA preparative regimen (usually fludarabine based) is designed not to eradicate the leukemia but to provide sufficient immunosuppression to allow engraftment of donor stem cells and development of a GVL effect. This strategy allows for treatment of patients who are older and/or have comorbidities that prevent use of standard high-dose ablative conditioning regimens.
Although follow-up is relatively short, NMA SCT is associated with a much lower cumulative and 100-day TRM compared with myeloablative SCT (16%-26% and 0%-5%, repectively, vs 38%-50% and 11%-29%, respec- ¶48 patients in CR (after miniChOP and F) randomized to autoSCT or observation, whereas 52 patients not in CR randomized to autoSCT or FC. #CD34 selection performed in 15 of 88 patients. **There were 325 patients (of which 83 underwent autoSCT). † †There were 128 of which 86% were chemotherapy-naive at study entry (only 98 proceeded to autoSCT tively) (Table 15) . [202] [203] [204] [205] 207, 211, 216 However, the incidences of grade 2 to grade 4 acute GVHD and chronic GVHD appear to be comparable in patients undergoing NMA or myeloablative SCT (9%-63% and 33%-75%, respectively, vs 37%-56% and 40%-85%, respectively). 195, [201] [202] [203] [204] [205] [206] [207] [209] [210] [211] [212] [213] [214] [215] [216] Data suggest that NMA SCT may overcome the negative prognostic impact of ZAP-70 positivity, unmutated V H gene status, and/or chromosomal abnormalities (such as 11q-and 17p-). 213, 217 The optimal conditioning regimen and strategy for prophylaxis of GVHD are unknown. Longer follow-up is required to determine whether remissions are durable, whether rates of relapse or disease progression are comparable to those achieved with myeloablative SCT, and whether the use of donor leukocyte infusions to achieve either full donor chimerism or control disease posttransplantation is effective. Controlled trials are required to determine whether NMA SCTs are superior to conventional chemotherapy in older patients and/or those not otherwise eligible for myeloablative SCT who have adverse prognostic factors. In view of these uncertainties, NMA SCT should be performed in the context of a clinical trial.
COMPLICATIONS
IMMUNE-MEDIATED CYTOPENIAS
Autoimmune Hemolytic Anemia. The prevalence of positive direct antiglobulin test (DAT) results in patients with CLL varies from 2% to 35%, with a higher prevalence with more advanced disease. [217] [218] [219] Clinically detectable autoimmune hemolytic anemia (AIHA) has been observed in 3% to 37% of patients, usually those with advanced-stage CLL.
99, [218] [219] [220] [221] [222] [223] Older age, male sex, and a higher lymphocyte count have also been associated with an increased rate of AIHA at CLL diagnosis. 221 In approximately one third of patients, AIHA will be diagnosed concurrently with the diagnosis of CLL. 221 However, the development of AIHA does not have a negative impact on OS. 221, 222 The precise pathogenesis of AIHA in patients with CLL is unclear. 219, 220 Most patients have a warm AIHA mediated by IgG antierythrocyte antibodies directed against antigens of the Rhesus system on red blood cells, whereas the remaining have a cold AIHA mediated by monoclonal IgM antibodies that can fix and activate complement [219] [220] [221] 224 ; rarely, patients will have a mixed type AIHA, with a combination of warm and cold autoantibodies. 225, 226 Autoimmune hemolytic anemia and CLL should be treated independently. 219, 220 For warm AIHA, corticosteroids are the standard initial therapy. 219, 220 If there is no response to corticosteroids, intravenous immunoglobulin (IVIG) should be added; however, response is usually transient, but retreatment is effective. Cyclosporine is a reasonable choice when corticosteroids and IVIG have failed. 219, 220, 227 Therapy with alemtuzumab alone or in combination with fludarabine, rituximab alone or in combination with fludarabine and cyclophosphamide or cyclophosphamide and dexamethasone, and splenectomy or splenic irradiation may be effective in refractory AIHA. 219, 220, [228] [229] [230] [231] [232] [233] [234] Blood transfusions may be required for symptomatic AIHA before a response occurs to primary therapy. Transfusion therapy may be complicated by phenotyping problems due to the presence of the autoantibodies, which typically reacts with all donor red blood cells. These autoantibodies can mask alloantibodies stimulated by previous transfusions or pregnancies and may contribute to allergic and febrile nonhemolytic transfusion reactions. 235 Nonetheless, donor blood can be safely and expeditiously provided. 236, 237 Immune-Mediated Thrombocytopenia. The true incidence of autoantibodies to platelets and other hematopoietic cells in patients with CLL is unknown because of the lack of available sensitive and reliable detection assays. 219, 238 Despite this, the presence of autoantibodies to platelets has been observed in 74% to 85% of patients with CLL, 239, 240 which is greater than the reported incidence of immune-mediated thrombocytopenia in patients with CLL (2%-4%). 219, 220, 222 About one third of patients with CLL and immune thrombocytopenia will also have either a positive DAT result or AIHA (ie, Evan syndrome). 220 The development of immune-mediated thrombocytopenia does not compromise survival. 222 The precise pathogenesis of thrombocytopenia in patients with CLL is unknown. 219, 220 Optimal therapy for immune-mediated thrombocytopenia is unclear given the small number of patients. Immune-mediated thrombocytopenia and CLL should be treated independently. 219, 220 The treatment strategy is based on recommendations made by the American Society of Hematology for the treatment of idiopathic thrombocytopenic purpura, with first-line therapy being corticosteroids. 241 Refractory autoimmune thrombocytopenia may respond to therapy with alemtuzumab or rituximab. 242, 243 Pure Red Cell Aplasia. Unlike AIHA, which is characterized by an increased number of reticulocytes, positive DAT, and elevated serum lactate dehydrogenase level, pure red cell aplasia (PRCA) is associated with reticulocytopenia and the absence of erythroid precursors in the bone marrow. 220 Pure red cell aplasia occurs in 1% to 6% of patients with CLL; however, the true incidence may be underestimated because patients are usually receiving myelosuppressive therapy or may have a positive DAT or a large spleen suggestive of hypersplenism. 219, 220, 222, 244 It may occur at the time of or several years after the diagnosis of CLL, regardless of the type of prior therapy, and does not appear to affect prognosis. 244 T-cell mediated inhibition of erythropoiesis plays a major role in the development of PRCA. 220, 244 Given the rarity of PRCA, assessing treatment efficacy is difficult. The underlying CLL must be treated concurrently to achieve long-term control of the PRCA. 220 Initially, PRCA is treated with corticosteroids. If no response occurs, cyclosporine is added. After normalization of the hemoglobin level, the corticosteroids are tapered and discontinued, and cyclosporine is continued for 5 to 7 months followed by a slow taper. 220 Also, PRCA may respond to therapy with rituximab and alemtuzumab. 242, 243, 245 Therapy-Related Autoimmunity. Alkylating agents, radiotherapy, and purine analogues may trigger hemolysis, PRCA, and/or immune thrombocytopenia. 95, 96, 98, 219, 223, 246 Most cases of AIHA associated with fludarabine have occurred in heavily pretreated patients, usually in those who have received a prior alkylating agent, irrespective of DAT status. 219, 220, 247 Most patients were responding to therapy at the time of development of AIHA; some, but not all, patients had a history of AIHA. 247 Development of treatment-associated AIHA and/or immune thrombocytopenia may be related to immunosuppression with a disturbance in the immunoregulatory T cells; immune tolerance is impaired with an inability to recognize self-antigens. 219, 220, 248 Recent data suggest that AIHA may occur more frequently in previously untreated patients who receive an alkylating agent than in those receiving fludarabine; fludarabine and cyclophosphamide chemotherapy may have a protective effect against the development of AIHA. 98, 99, 223 Successful treatment of autoimmunity after fludarabine therapy has been reported with use of corticosteroids, rituximab, and cyclosporine. 227, 247, [249] [250] [251] [252] Recurrence of AIHA or immune thrombocytopenia after reexposure to purine analogues has been reported. 220, 247, 248, 253 It is unclear whether this can be prevented by administering purine analogues with an alkylating agent or cyclosporine. 227 Because life-threatening and sometimes fatal AIHA has been reported, it would appear prudent not to rechallenge these patients with a purine analogue.
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INFECTIONS
The types of infections, risk factors, and therapy-associated immune defects in patients with CLL have been extensively reviewed recently. [254] [255] [256] It is estimated that up to 70% of patients will develop infections, with incidences varying from as low as 0.009 per patient-year to as high as 1.82 per patient-year depending on the group of CLL patients. Furthermore, up to 55% of deaths in patients with CLL are attributed to infections.
Because of the lack of randomized trials, strategies for preventing infections in patients with CLL should be guided by the patient's age, stage of disease, extent of prior therapy, and immunosuppressive properties of the antineoplastic agent being administered. Intravenous immunoglobulin has been shown to decrease the incidence of bacterial infections in patients with CLL. 257, 258 However, given the expense, lack of improvement in OS, and the effectiveness of less-expensive antibiotics, the role of IVIG is limited in patients with CLL 259 but may be warranted in patients with hypogammaglobulinemia and recurrent sinopulmonary infections. [254] [255] [256] Growth factors may reduce the severity and duration of neutropenia associated with nucleoside analogues; however, their routine use remains to be established. 255 Concomitant use of nucleoside analogues and corticosteroids should be avoided. Despite the lack of randomized trials demonstrating the effectiveness of Pneumocystis jirovecii (formerly P carinii) prophylaxis in this patient population, some have advocated prophylaxis for all patients receiving purine analogues and/or alemtuzumab because of the high mortality rate in infected individuals. 254 Similarly, given the morbidity associated with varicella zoster viral infections, prophylaxis in older seropositive patients with low CD4 counts and those receiving therapy with alemtuzumab may be warranted. 256, 260 Patients should also be screened before and monitored during and after alemtuzumab therapy for CMV reactivation and infections. 260 Recent data from a single-center randomized study indicated that valganciclovir can effectively prevent CMV reactivation compared with valacyclovir (0% vs 35%; P=.004).
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SECOND MALIGNANCIES
Second cancers, including Kaposi sarcoma, malignant melanoma, cancers of the larynx and lung, brain cancer, and cancers of the stomach and bladder, have been observed in up to 11% of patients with CLL. 92, [262] [263] [264] [265] The overall risk of developing a second cancer was modestly but significantly elevated, independent of initial treatment, in patients with CLL compared with those in the general population. Differences in cancer distribution have been associated with sex and age. [262] [263] [264] The increased incidence of second neoplasms in patients with CLL may be related to immunologic impairment associated with CLL 255 and/or heightened responses to carcinogens, such as tobacco smoke and excessive sunlight, but does not appear to be related to therapy. 262, 264, 265 Given the long survival of patients with CLL, they should be monitored for the occurrence of second malignancies and urged to avoid exposures to carcinogens, such as tobacco smoke and excessive sunlight.
The development of AML or MDS in patients with CLL is uncommon (1%), but it has been reported in both untreated and treated patients and can be detected concur-rently. 53, [265] [266] [267] [268] [269] [270] [271] [272] [273] It is unclear whether the development of MDS or AML occurs from clonal evolution or independent transforming events. 269, 271, 273 An increased frequency of therapy-related MDS and/or AML has been observed in patients treated with fludarabine and chlorambucil therapy compared with single-agent fludarabine or chlorambucil. 95, 107 Patients with CLL in whom AML or MDS develops appear to have prognoses similar to those with de novo AML or MDS.
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DISEASE TRANSFORMATION
Transformation of CLL to an aggressive form of disease, either PLL (with >55% circulating prolymphocytes) or Richter syndrome (RS) (large cell lymphoma or immunoblastic lymphoma), occurs in a small proportion of patients. [274] [275] [276] [277] [278] [279] [280] [281] [282] Transformation to acute lymphocytic leukemia, Hodgkin lymphoma, and multiple myeloma has also been described.
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Richter Syndrome. Up to 10% of patients with B-CLL/ SLL will undergo histological transformation to RS. Features associated with RS include systemic symptoms, rapidly progressive lymphadenopathy, extranodal disease, monoclonal gammopathy, and an elevated lactate dehydrogenase level. Other findings include hepatosplenomegaly, anemia, thrombocytopenia, and atypical extranodal sites of involvement (eg, brain, respiratory tract, skin, and gastrointestinal tract). 282, 283 Although these features are unusual in CLL, none are pathognomic for RS. The pathophysiology has been extensively reviewed. 274, 282 Treatment of RS has commonly involved chemotherapeutic regimens traditionally used for NHL, such as the alkylating agent-based, anthracycline-based, and cytarabine/ platinum regimens, as well as therapies for the treatment of Hodgkin lymphoma. These regimens have produced OR rates of 25% to 41% (PR, 6%-15%; CR, 10%-34%). 274 However, median survival after transformation to RS is less than 6 months. Therapy with newer regimens, eg, hyperCVXD (fractionated cyclophosphamide, vincristine, liposomal daunorubicin [daunoXome], and dexamethasone) augmented hyperCVXD, and yttrium-90 ibritumomab tiuxetan, has not produced major improvements in response rates or OS.
In a small series of 12 patients treated with allogeneic SCT, 3 patients remained alive and in remission at 14, 47, and 67 months, respectively. 211, [284] [285] [286] At the time of transplantation, only 3 patients had achieved a CR or PR, including 2 of the 3 patients who were still alive after allogeneic SCT. These favorable results compared to those obtained with chemotherapy alone need to be confirmed in a larger series of patients.
Prolymphocytic Leukemia. Because of the relative rarity of cases, [275] [276] [277] [278] [279] [280] [281] discrepancies in the percentage of circulating prolymphocytes required for a diagnosis of PLL transformation, and lack of serial blood work available for assessment, 277, 278, 281 data are extremely limited with respect to not only the incidence of PLL transformation but also the median time to transformation, OS, and optimal therapy. [277] [278] [279] [280] In a small series of patients with typical CLL who had serial blood films available for review, most had minor variations or transient increases in the percentage of circulating prolymphocytes, and one third had a steady increase in the proportion of prolymphocytes (but always <55%). 287 In contrast, 19% of patients with CLL/PLL (defined by the presence of 11%-55% prolymphocytes) had progression to a PLL-like picture. 287 Features associated with transformation include leukocytosis (white blood cell count >100 × 10 9 /L), splenomegaly, hepatomegaly, and lymphadenopathy; central nervous system involvement 288-290 and development of malignant ascites, pleural effusions, and periorbital swelling have been described. 291, 292 Median age at transformation was 76 years (range, 64-82 years). [275] [276] [277] [278] [279] [280] Median time to transformation and survival from the time of transformation were 38 months (range, 15-192 months) and 5 months (range, <1-27.5 months), respectively. [275] [276] [277] [278] [279] [280] Optimal therapy, including the role of SCT, is unclear.
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SUMMARY
Important changes in the understanding and management of CLL have occurred in the past 2 decades. With the advent of newer treatment modalities, such as purine analogues and monoclonal antibodies, substantial improvements have been made in achieving CRs, with a proportion achieving molecular remissions and durable responses, which may translate into increased survival for these patients. Allogeneic myeloablative SCT may benefit younger patients but is still associated with pronounced treatmentrelated mortality and morbidity. Nonmyeloablative SCT is associated with less toxicity, but its role in the treatment of CLL remains to be defined. Future therapy will be modified by the integration of prognostic factors into the treatment alogorithm.
